AveXis, Inc.

AveXis, a Novartis company, is the world’s leading gene therapy company, redefining the possibilities for patients and families affected by life-threatening genetic diseases through our innovative gene therapy platform. Founded in 2013 and headquartered in Bannockburn, IL, the goal of AveXis’ cutting-edge science is to address the underlying, genetic root cause of diseases. AveXis pioneered foundational research, establishing AAV9 as an ideal vector for gene transfer in diseases affecting the central nervous system, laying the groundwork to build a best-in-class, transformational gene therapy pipeline. AveXis received its first U.S. Food and Drug Administration approval in May 2019 for the treatment of spinal muscular atrophy (SMA). AveXis is also developing therapies for other genetic diseases, including Rett syndrome and a genetic form of amyotrophic lateral sclerosis (ALS) SOD1.Read Our Community Guidelines: https://bit.ly/2V4AjC5 How to reach us:AveXis, Inc.2275 Half Day Road, Suite 200Bannockburn, IL 60015Email: [email protected] Phone: 847.572.8280Toll-free Phone: 844.4.AVEXIS (844.428.3947)